XTalks

MAY 26, 2023

Krystal Biotech’s Vyjuvek has been awarded US Food and Drug Administration (FDA) approval to make it the first topical gene therapy for the treatment of wounds in patients with the rare, often debilitating skin disease dystrophic epidermolysis bullosa (DEB). As a topical treatment, it is also the first readily redosable gene therapy.

Gene Therapy 97

Gene Therapy Gene Dermatology FDA Approval 97

pharmaphorum

DECEMBER 15, 2020

Eli Lilly has acquired Prevail, a biotech focusing on gene therapies for neurodegenerative diseases including Parkinson’s, in a deal potentially worth more than $1 billion. The CVR pays out if one of Prevail’s gene therapies is approved in one of several developed countries before December 31, 2024.

Gene Therapy 69

Gene Therapy Gene Dermatology Trials 69

Scienmag

FEBRUARY 18, 2021

Mount Sinai researchers have discovered that Polycomb complexes, groups of proteins that maintain gene expression patterns, are essential for proper skin development, according to a paper published in Genes & Development on February 18.

Gene Expression 72

Gene Expression Development Research Gene 72

The Pharma Data

NOVEMBER 4, 2020

TSX: CTX) (OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house research & development (“R&D”) and manufacturing capabilities, today announced that it has entered into an exclusive agreement with Juyou-Biotechnology Co.

Licensing 40

Licensing Licensing Dermatology Production 40

The Pharma Data

JANUARY 13, 2021

Brilacidin is a first-in-class Host Defense Protein (HDP) mimetic with antiviral, anti-inflammatory and antibacterial properties. Food and Drug Administration (FDA) has designated as a Fast Track development program the investigation of Brilacidin as a potential treatment for COVID-19.

Clinical Trials 52

Clinical Trials Clinical Trials Trials In-Vitro 52

The Pharma Data

MARCH 16, 2021

These data will be presented virtually in abstract, poster, and video form during the Innovations in Dermatology: Virtual Spring Conference, March 16–20, 2021. 26 Although the exact cause of PsA is unknown, genes, the immune system and environmental factors are all believed to play a role in disease onset.

Medicine 52

Medicine Doctors Doctor Development 52

The Pharma Data

AUGUST 3, 2021

Aimovig retains strong payer coverage and remains the segment leader within the preventive calcitonin gene-related peptide (CGRP) class. We expect that recovery in the dermatology segment will continue to progress over the coming quarters. and continued geographic expansion, including the launch in China. Efavaleukin alfa (AMG 592).

Sales 52

Sales Production Antibody Development 52